TC BioPharm (TCBP) shares rose as much as almost 25% in recent trading Tuesday after the company said that negotiations with its acquisition targets are progressing.
The company is looking to expand its therapeutic platform through acquisitions focusing on new indications and cell therapy approaches.
"Management is currently negotiating deal terms in good faith, and I believe the process is progressing to mutually beneficial outcomes," TC BioPharm Chief Executive Bryan Kobel said.
The company did not identify the acquisition candidates.
Price: 0.64, Change: +0.03, Percent Change: +5.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments